3,572 results match your criteria Thyroid Anaplastic Carcinoma

An Evaluation of Clinical Efficacy of Immune Checkpoint Inhibitors for Patients with Anaplastic Thyroid Carcinoma.

Thyroid 2022 May 18. Epub 2022 May 18.

The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute, 24600, 460 W. 10th Avenue Columbus, Columbus, Ohio, United States, 43210-1240;

Background: Anaplastic thyroid cancer (ATC) is an aggressive thyroid malignancy which is associated with a poor prognosis. Current treatment options include surgery, radiation, cytotoxic chemotherapy, and multikinase inhibitor therapy. The role of immunotherapy in ATC is an area of active interest and recent evidence suggests that it may be a potentially effective treatment option. Read More

View Article and Full-Text PDF

Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.

Front Endocrinol (Lausanne) 2022 27;13:859013. Epub 2022 Apr 27.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

Background: Patients with advanced thyroid carcinoma (TC), such as anaplastic thyroid carcinoma (ATC), poorly differentiated thyroid carcinoma (PDTC), and locally advanced papillary thyroid carcinoma (PTC), have poor prognoses and require novel treatments. Immune checkpoint (ICP) inhibitors have demonstrated encouraging and good results; nevertheless, their effect in advanced TCs remains largely unclear. Thus, we demonstrated ICP profiles and investigated their potential clinical significance. Read More

View Article and Full-Text PDF

Expression of colorectal neoplasia differentially expressed in anaplastic thyroid carcinoma and its effect on cancer cell proliferation.

Ann Transl Med 2022 Apr;10(8):473

Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.

Background: The incidence of anaplastic thyroid cancer (ATC) is high among human cancers. Colorectal neoplasia differentially expressed (CRNDE) is highly expressed in common tumors, and is therefore a potential molecular target for anti-tumor therapy. However, the function of CRNDE in ATC remains elusive. Read More

View Article and Full-Text PDF

To Detach, Migrate, Adhere, and Metastasize: CD97/ in Cancer.

Cells 2022 May 4;11(9). Epub 2022 May 4.

Research Laboratories of the Clinic of Visceral, Transplantation, Thoracic, and Vascular Surgery, Medical School, University Hospital Leipzig, Leipzig University, 04103 Leipzig, Germany.

Tumorigenesis is a multistep process, during which cells acquire a series of mutations that lead to unrestrained cell growth and proliferation, inhibition of cell differentiation, and evasion of cell death. Growing tumors stimulate angiogenesis, providing them with nutrients and oxygen. Ultimately, tumor cells invade the surrounding tissue and metastasize; a process responsible for about 90% of cancer-related deaths. Read More

View Article and Full-Text PDF

First-in-Human Experience With 177Lu-DOTAGA.(SA.FAPi)2 Therapy in an Uncommon Case of Aggressive Medullary Thyroid Carcinoma Clinically Mimicking as Anaplastic Thyroid Cancer.

Clin Nucl Med 2022 Jun 4;47(6):e444-e445. Epub 2022 Apr 4.

From the Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.

Abstract: A 56-year-old man was diagnosed with calcitonin negative, plasma chromogranin A-positive, immunohistochemistry-negative, high-grade MTC (medullary thyroid cancer) behaving clinically like anaplastic thyroid cancer and presented with progressive disease after conventional therapies. A theranostic approach of 68Ga-DOTA.SA. Read More

View Article and Full-Text PDF

Laryngotracheal resection after B-Raf proto-oncogene inhibition for anaplastic thyroid carcinoma.

Ann Thorac Surg 2022 Apr 30. Epub 2022 Apr 30.

Department of Surgery, University of Chicago, Chicago, Illinois.

Anaplastic thyroid carcinoma (ATC) is a rare but aggressive neoplasm that often presents as advanced inoperable disease. Patients with B-Raf proto-oncogene (BRAF) v600e mutated ATC who receive neoadjuvant Dabrafenib/Trametinib have improved rates of microscopically margin negative resection and durable locoregional control. However, this has not been evaluated in the setting of tracheal resection and primary reconstruction. Read More

View Article and Full-Text PDF

GANT61 suppresses cell survival, invasion and epithelial-mesenchymal transition through inactivating AKT/mTOR and JAK/STAT3 pathways in anaplastic thyroid carcinoma.

Cancer Biol Ther 2022 Dec;23(1):369-377

Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Glioma-associated oncogene (Gli) antagonist-61 (GANT61) not only suppresses the malignant behavior of several cancers but also presents synergistic effects with other anticancer agents on suppressing the progression of cancers, while relevant information is rare in anaplastic thyroid carcinoma (ATC). This study aimed to explore the therapeutic effect of GANT61 in ATC and its molecular mechanism. ATC cells (8505C and CAL-62) were treated with GANT61, followed by detection of cell proliferation, apoptosis, invasion and epithelial-mesenchymal transition (EMT) markers. Read More

View Article and Full-Text PDF
December 2022

Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses.

Front Oncol 2022 5;12:854755. Epub 2022 Apr 5.

Department of Surgical, Medical, Molecular Pathology and Critical Area, Unit of Endocrine Surgery, University Hospital of Pisa, Pisa, Italy.

Background: Large thyroid masses, particularly if rapidly growing, are often characterized by compression and infiltration of the vital structures of the neck. Therefore, an early and precise diagnosis, not only of malignancy but also of histotype, is mandatory to set up the right therapy. The aim of this study was to evaluate the diagnostic performance of fine needle aspiration cytology (FNAC) and core needle biopsy (CNB) in this setting. Read More

View Article and Full-Text PDF

Revisiting Combination Chemotherapy as a Single Modality Palliative Therapy for Advanced Anaplastic Thyroid Carcinoma-a Single Institution Experience.

Indian J Surg Oncol 2022 Mar 2;13(1):208-215. Epub 2021 Aug 2.

Department of Endocrine Surgery, King George's Medical University, Lucknow, UP India.

Anaplastic thyroid carcinoma (ATC) is an aggressive malignancy with dismal outcome especially in metastatic setting. Consensus for ideal treatment of advanced and metastatic ATC remains elusive. This study aimed to analyze the impact of palliative chemotherapy versus supportive care on overall survival in patients with metastatic anaplastic thyroid carcinoma. Read More

View Article and Full-Text PDF

Utilizing Three-Dimensional Culture Methods to Improve High-Throughput Drug Screening in Anaplastic Thyroid Carcinoma.

Cancers (Basel) 2022 Apr 7;14(8). Epub 2022 Apr 7.

Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA.

Anaplastic thyroid carcinoma (ATC) is the most aggressive endocrine neoplasm, with a median survival of just four to six months post-diagnosis. Even with surgical and chemotherapeutic interventions, the five-year survival rate is less than 5%. Although combination dabrafenib/trametinib therapy was recently approved for treatment of the ~25% of ATCs harboring mutations, there are no approved, effective treatments for -wildtype disease. Read More

View Article and Full-Text PDF

Curative surgery for anaplastic thyroid carcinoma: A case report.

SAGE Open Med Case Rep 2022 14;10:2050313X221091399. Epub 2022 Apr 14.

Department of Surgery, National Hospital Kandy, Kandy, Sri Lanka.

Anaplastic thyroid carcinoma accounts for 3%-4% of thyroid malignancies worldwide and is aggressive in nature with a median survival of 6 months at diagnosis. A 67-year-old lady with a hard goitre presented with compressive symptoms and mild hypothyroidism. Ultrasound scan revealed a Thyroid Imaging Reporting and Data System 5 lesion with suspicious left-sided cervical lymphadenopathy. Read More

View Article and Full-Text PDF

Pulmonary inflammatory myofibroblastic tumor coexisting with lymphangitis carcinomatosis: Mimicking metastatic papillary thyroid carcinoma with nodular fasciitis-like stroma.

Indian J Pathol Microbiol 2022 Apr-Jun;65(2):422-425

Department of Surgical Pathology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.

Inflammatory myofibroblastic tumors (IMTs) are uncommon; intermediate grade soft tissue tumors occurring in young individuals with an uncertain behaviour. The incidence of pulmonary lymphangitis carcinomatosis (PLC) is around 6-8% of all pulmonary metastases. However, PLC due to papillary thyroid carcinoma (PTC) is very uncommon. Read More

View Article and Full-Text PDF

Surgical resection of the primary tumor prevents an undesirable locoregional condition and improves the quality of life in patients with anaplastic thyroid cancer.

Surg Today 2022 Apr 17. Epub 2022 Apr 17.

Division of Breast and Endocrine Surgery, Department of Surgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-861, Japan.

Purpose: Anaplastic thyroid cancer (ATC) is a highly aggressive tumor that invades surrounding tissues and rapidly metastasizes throughout the body. Growth of the primary tumor in the neck often causes serious conditions that decrease the quality of life (QOL) of patients. The objective of this study was to investigate the role of surgical resection in improving the QOL of patients with ATC. Read More

View Article and Full-Text PDF

A signature of circadian rhythm genes in driving anaplastic thyroid carcinoma malignant progression.

Cell Signal 2022 Apr 14;95:110332. Epub 2022 Apr 14.

Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China 310014; Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, China. Electronic address:

Background: Anaplastic thyroid carcinoma (ATC) was a rare and extremely malignant endocrine cancer. Recently, dysregulation of circadian rhythm genes was demonstrated to play an essential role in tumor progression, while its exact role and mechanism in ATC remained poorly clear.

Methods: 4 ATC-related datasets were integrated to screen for differentially expressed circadian rhythm genes (DE-CRGs). Read More

View Article and Full-Text PDF

Interpreting the Pharmacological Mechanisms of Sho-saiko-to on Thyroid Carcinoma through Combining Network Pharmacology and Experimental Evaluation.

ACS Omega 2022 Apr 25;7(13):11166-11176. Epub 2022 Mar 25.

Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

Sho-saiko-to is a well-known traditional Chinese medicine compound and is considered to have therapeutic effects against many diseases, including thyroid cancer (TC). However, the mechanisms and therapeutic targets of Sho-saiko-to against TC remain unclear. In this study, network pharmacology, molecular docking, and cell experiments were combined to predict and verify the targets and mechanisms of the active ingredients of Sho-saiko-to against TC. Read More

View Article and Full-Text PDF

In Vitro and In Vivo Effects of the Urokinase Plasminogen Activator Inhibitor WX-340 on Anaplastic Thyroid Cancer Cell Lines.

Int J Mol Sci 2022 Mar 28;23(7). Epub 2022 Mar 28.

Department of Surgical Sciences, "Sapienza" University of Rome, 00161 Rome, Italy.

Increased expression of the urokinase-type plasminogen activator (uPA) system is associated with tumor invasion, neo-angiogenesis, and metastatic spread, and has been shown to positively correlate with a poor prognosis in several cancer types, including thyroid carcinomas. In recent years, several uPA inhibitors were found to have anticancer effects in preclinical studies and in some phase II clinical trials, which prompted us to evaluate uPA as a potential therapeutic target for the treatment of patients affected by the most aggressive form of thyroid cancer, the anaplastic thyroid carcinoma (ATC). In this study, we evaluated the in vitro and in vivo effects of WX-340, a highly specific and selective uPA inhibitor, on two ATC-derived cell lines, CAL-62 and BHT-101. Read More

View Article and Full-Text PDF

Comparative Proteomic Profiling of Ectosomes Derived from Thyroid Carcinoma and Normal Thyroid Cells Uncovers Multiple Proteins with Functional Implications in Cancer.

Cells 2022 03 31;11(7). Epub 2022 Mar 31.

Department of Glycoconjugate Biochemistry, Faculty of Biology, Institute of Zoology and Biomedical Research, Jagiellonian University in Krakow, 30-387 Krakow, Poland.

Proteins carried by tumor-derived ectosomes play an important role in cancer progression, and are considered promising diagnostic markers. In the present study, a shotgun nanoLC-MS/MS proteomic approach was applied to profile and compare the protein content of ectosomes released in vitro by normal human thyroid follicular epithelial Nthy-ori 3-1 cells and human anaplastic thyroid carcinoma (TC) 8305C cells. Additionally, the pro-migratory and pro-proliferative effects of Nthy-ori 3-1- and 8305C-derived ectosomes exerted on the recipient cells were assessed in wound closure and Alamar Blue assays. Read More

View Article and Full-Text PDF

USP26 promotes anaplastic thyroid cancer progression by stabilizing TAZ.

Cell Death Dis 2022 Apr 9;13(4):326. Epub 2022 Apr 9.

Department of Liver Surgery, Xiangya Hospital, Clinical Research Center for Breast Cancer Control and Prevention in Hunan Province, Central South University, Changsha, China.

Anaplastic thyroid cancer (ATC) is one of the most lethal and aggressive human malignancies, with no effective treatment currently available. The Hippo tumor suppressor pathway is highly conserved in mammals and plays an important role in carcinogenesis. TAZ is one of major key effectors of the Hippo pathway. Read More

View Article and Full-Text PDF

GAB1 is upregulated to promote anaplastic thyroid cancer cell migration through AKT-MDR1.

Biochem Biophys Res Commun 2022 06 26;607:36-43. Epub 2022 Mar 26.

Department of Pathology and Pathophysiology and Department of Cardiology of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address:

Anaplastic thyroid carcinoma (ATC) represents an undifferentiated, aggressive and highly metastatic form of thyroid cancer with high mortality. GAB1, through direct interaction with the kinase PI3K and phosphatase SHP2, is tightly involved in the activation of oncogenic signals; however, the role of GAB1 in ATC remains unclear. GAB1 was significantly increased in ATC, accompanied with AKT activation. Read More

View Article and Full-Text PDF

Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma.

Endocrine 2022 Apr 2. Epub 2022 Apr 2.

Department of Otorhinolaryngology Head and Neck Surgery, Shanghai Pudong New Area Gongli Hospital, Shanghai, 200135, China.

Background: Mutations in DNA mismatch repair (MMR) genes associated with thyroid carcinoma (TC) have rarely been reported, especially in East Asian populations.

Methods: We examined tumor tissue from a cohort of 241 patients diagnosed with TC between 2008 and 2020. MMR proteins were detected using tissue microarray-based immunohistochemistry in order to identify MMR-protein-deficient (MMR-D) and MMR-protein-intact (MMR-I) tumors. Read More

View Article and Full-Text PDF

Differences Between Cancer-Specific Survival of Patients With Anaplastic and Primary Squamous Cell Thyroid Carcinoma and Factors Influencing Prognosis: A SEER Database Analysis.

Front Endocrinol (Lausanne) 2022 10;13:830760. Epub 2022 Mar 10.

Bioinformatics and Biomedical Big Data Mining Laboratory, Department of Medical Informatics, School of Big Health, Guizhou Medical University, Guiyang, China.

Purpose: Anaplastic thyroid carcinoma (ATC) and primary squamous cell carcinoma of the thyroid (PSCCTh) have similar histological findings and are currently treated using the same approaches; however, the characteristics and prognosis of these cancers are poorly researched. The objective of this study was to determine the differences in characteristics between ATC and PSCCTh and establish prognostic models.

Patients And Methods: All variables of patients with ATC and PSCCTh, diagnosed from 2004-2015, were retrieved from the Surveillance, Epidemiology, and End Results Program (SEER) database. Read More

View Article and Full-Text PDF

A novel prognostic model based on log odds of positive lymph nodes to predict outcomes of patients with anaplastic thyroid carcinoma after surgery.

Clin Endocrinol (Oxf) 2022 Mar 31. Epub 2022 Mar 31.

Peking Union Medical College Graduate School, Beijing, China.

Objective: The eighth version of the American Joint Committee on Cancer (8th AJCC) system for anaplastic thyroid carcinoma (ATC) added lymph node (LN) metastasis as the staging element. This study aimed to explore the association between LN status and ATC's prognosis, identify the optimal LN index and establish a novel prognostic model.

Design And Patients: Data of 199 ATC patients after surgery were collected from the Surveillance, Epidemiology and End Results (SEER) database, then randomly divided into training and validation cohorts. Read More

View Article and Full-Text PDF

TROP2: a potential marker in diagnosis of thyroid neoplasms.

Ir J Med Sci 2022 Mar 30. Epub 2022 Mar 30.

Department of Pathology, Gaziantep University Medical Faculty Hospital, Gaziantep, Turkey.

Background And Objectives: The human trophoblast cell surface antigen (TROP-2), a transmembrane glycoprotein, has recently been investigated as a valuable marker of thyroid epithelial neoplasms. In this study, we aimed to demonstrate the diagnostic utility of TROP2 in thyroid neoplasms.

Methods: A total of 308 cases, including 170 cases of different PTC variants, 50 cases of benign and non-neoplastic lesions, and 86 cases of other neoplasms (NIFT-P, poorly differentiated thyroid carcinoma, anaplastic thyroid carcinoma, follicular thyroid carcinoma, Hürthle cell carcinoma, and medullary thyroid carcinoma), were included in this study. Read More

View Article and Full-Text PDF

Cadherin-16 inhibits thyroid carcinoma cell proliferation and invasion.

Oncol Lett 2022 May 15;23(5):145. Epub 2022 Mar 15.

Department of Endocrinology (Section I), Tangshan Gongren Hospital, Tangshan, Hebei 063000, P.R. China.

Cadherin-16 (CDH16), a member of the cadherin family of adhesion molecules, serves an important role in the formation and maintenance of the thyroid follicular lumen. Decreased expression of CDH16 has been reported to be associated with tumor stage in papillary thyroid cancer (PTC); however, previous analyses have been limited and the biological role of CDH16 in different subtypes of TC is unknown. To investigate the role of CDH16 in the occurrence and development of TC, bioinformatic analysis of three TC subtypes (PTC, follicular cell-derived TC and anaplastic TC) was performed using an extended data set from the Gene Expression Omnibus database, with additional confirmation using data from The Cancer Genome Atlas, as well as biopsies from 35 patients with PTC and TC or follicular cell lines. Read More

View Article and Full-Text PDF

Anaplastic Thyroid Carcinoma with Ocular Then Orbital Metastases.

Case Rep Ophthalmol 2022 Jan-Apr;13(1):76-81. Epub 2022 Feb 14.

Gavin Herbert Eye Institute, University of California, Irvine, Irvine, California, USA.

A 52-year-old Hispanic woman with a history of metastatic thyroid carcinoma presented with left eye degeneration and a choroidal mass without evidence of orbital disease on neuroimaging. She underwent enucleation for a blind, painful eye. Histopathology demonstrated choroidal metastasis of thyroid carcinoma with a well-circumscribed episcleral nodule, consistent with extraocular tumor extension. Read More

View Article and Full-Text PDF
February 2022

Advances in targeted therapy for anaplastic thyroid carcinoma.

Zhejiang Da Xue Xue Bao Yi Xue Ban 2021 Dec;50(6):685-693

1. Graduate School, Bengbu Medical College, Bengbu 233030, Anhui Province, China.

Anaplastic thyroid carcinoma (ATC) is a highly malignant and aggressive thyroid malignancy with rapid onset and poor prognosis. There is no effective treatment for ATC yet. Molecular targeted therapy provides a new idea for ATC treatment. Read More

View Article and Full-Text PDF
December 2021

Immunotherapy for anaplastic thyroid carcinoma: the present and future.

Zhejiang Da Xue Xue Bao Yi Xue Ban 2021 Dec;50(6):675-684

1. Department of Head and Neck Surgery, Center of Otolaryngology, Head and Neck Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, Hangzhou 310014, China.

Anaplastic thyroid carcinoma (ATC) is the most malignant tumor of endocrine system, which is an urgent medical problem to be solved. At present, immunotherapy studies on ATC mainly include cutting off the recruitment of tumor-associated macrophage (TAM), inducing the reprogramming of TAM and restoring its phagocytic function, targeting related immune checkpoints on T cells and natural killer cells, tumor vaccines based on oncolytic viruses and dendritic cells, and adoptive immunotherapy. Among them, immunotherapy strategies represented by targeted blocking of programmed death-1/programmed death ligand-1 at immune checkpoint have been preliminarily confirmed to benefit ATC patients, especially the combination of molecular targeted inhibitors and immunotherapy has shown excellent therapeutic effects. Read More

View Article and Full-Text PDF
December 2021

Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma.

Endocr Relat Cancer 2022 May 9;29(6):307-319. Epub 2022 May 9.

Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Dabrafenib is a BRAF kinase inhibitor approved for treatment of BRAF-mutated anaplastic thyroid carcinoma (ATC) in combination with trametinib. Erlotinib is a tyrosine kinase inhibitor of EGF receptor (EGFR). We evaluated effects of dabrafenib and erlotinib combination treatment on ATC cells in vitro and in vivo. Read More

View Article and Full-Text PDF

Clinicopathological indicators for TERT promoter mutation in papillary thyroid carcinoma.

Clin Endocrinol (Oxf) 2022 Mar 28. Epub 2022 Mar 28.

Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.

Objective: Mutations in the telomerase reverse transcriptase (TERT) promoter have been reported as a convincing prognostic factor in papillary thyroid carcinomas (PTCs). We aimed to investigate the frequency of TERT promoter mutations in patients with thyroid cancer and identify the clinicopathological factors associated with them in PTCs.

Design: A total of 1086 consecutive cases of thyroid cancer composed of mostly PTCs were included in this study. Read More

View Article and Full-Text PDF